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Abstract
In this study, we investigated the effect of glutamine (Gln) supplementation on the signaling pathways regulating protein
synthesis and protein degradation in the skeletal muscle of rats with streptozotocin (STZ)-induced diabetes. The expression
levels of key regulatory proteins in the synthetic pathways (Akt, mTOR, GSK3 and 4E-BP1) and the degradation pathways
(MuRF-1 and MAFbx) were determined using real-time PCR and Western blotting in four groups of male Wistar rats; 1)
control, non-supplemented with glutamine; 2) control, supplemented with glutamine; 3) diabetic, non-supplemented with
glutamine; and 4) diabetic, supplemented with glutamine. Diabetes was induced by the intravenous injection of 65 mg/kg
bw STZ in citrate buffer (pH 4.2); the non-diabetic controls received only citrate buffer. After 48 hours, diabetes was
confirmed in the STZ-treated animals by the determination of blood glucose levels above 200 mg/dL. Starting on that day, a
solution of 1 g/kg bw Gln in phosphate buffered saline (PBS) was administered daily via gavage for 15 days to groups 2 and
4. Groups 1 and 3 received only PBS for the same duration. The rats were euthanized, and the soleus muscles were removed
and homogenized in extraction buffer for the subsequent measurement of protein and mRNA levels. The results
demonstrated a significant decrease in the muscle Gln content in the diabetic rats, and this level increased toward the
control value in the diabetic rats receiving Gln. In addition, the diabetic rats exhibited a reduced mRNA expression of
regulatory proteins in the protein synthesis pathway and increased expression of those associated with protein
degradation. A reduction in the skeletal muscle mass in the diabetic rats was observed and was alleviated partially with Gln
supplementation. The data suggest that glutamine supplementation is potentially useful for slowing the progression of
muscle atrophy in patients with diabetes.
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Introduction
The maintenance of normal skeletal muscle mass and size is
required for locomotion, heat production and the control of
intermediary metabolism [1] and is dependent upon many factors,
including the functioning of efferent motor innervation [2] and an
adequate supply of glucose, fatty acids, and trophic hormones [3].
Diabetes mellitus, a disease affecting a quarter of a billion people
worldwide [4], can cause skeletal muscle damage and atrophy via
diabetic neuropathy and by the more direct effects of high glucose
and low insulin [3] on muscle cell metabolism. Indeed, insulin is a
major factor in the maintenance of the skeletal muscle protein
mass [2,5].
Muscle wasting in diabetes is ultimately the result of damage to
the intracellular signaling pathways that are involved in main-
taining the balance between protein degradation and new protein
synthesis [5], which depends on both the phosphorylation and de
novo expression of specific regulatory proteins. Specifically, the
skeletal muscle mass is ultimately controlled by the signaling
pathways leading to protein synthesis, especially the IGF-1/PI3K/
Akt pathway and alternatively, pathways leading to degradation,
such as MuRF-1- or MAFbx-dependent pathway intermediates
[2,6]. Depending on the physiologic state of the muscle cell, Akt
transduces signals that lead primarily to increased protein synthesis
(by activating a number of specific downstream proteins, including
mTOR, p70s6k, 4E-BP1 and GSK3) or to decreased degradation
(using pathways dependent upon MuRF-1 and MAFbx). Ulti-
mately, the disruption of either pathway results in the increase in
the overall muscle mass. In the protein synthetic pathway, Akt
activation leads to the formation of a signaling complex termed
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TORC1, an important component of mTOR [7]. The activation
of mTOR, in turn, induces the phosphorylation of p70S6K
(activates the ribosomal subunit required for muscle protein
translation) [8] and the translational repressor 4E-BP1, which is
inactivated following phosphate addition [9].
The degradation pathway utilizes the ubiquitin ligases atrogin-1
(MAFbx) and MuRF1, and the increased expression of these
enzymes is considered among the most reliable markers of muscle
atrophy and wasting [10,11]. The up-regulation of ubiquitin
ligase, however, is inhibited by Akt via a mechanism involving
members of the FOXO family of transcription factors [12,13].
Specifically, Akt phosphorylates FOXOs (pFOXO), thereby
promoting their migration from the nucleus to the cytosol. The
reduction in the activity of the Akt pathway, as reported for several
muscle atrophy models, causes a decrease in the cytosolic pFOXO
and an increase in the nuclear FOXO protein that allows the up-
regulation of atrogin-1/MAFbx and MuRF-1 and an increase in
muscle atrophy [14].
Skeletal muscle overloading is a key activator of PI3K/Akt,
leading eventually to muscle fiber hypertrophy [15]. TSC2, one of
the proteins regulated by Akt kinase, is a constitutively active
inhibitor of mTOR activity, and its activity is suppressed by the
phosphorylation of specific amino acid residues. The result is an
increase in protein translation and ultimately in muscle mass.
Recently, it has been shown that the non-essential amino acid
glutamine (Gln) may have a positive influence on the protein
synthesis downstream of mTOR activation in a HeLa cell model
[16]. It has been suggested that the mTOR activation in these cells
is dependent on the uptake and subsequent rapid efflux of
glutamine in the presence of essential amino acids [16].
Glutamine, at a concentration 0.5–0.8 mM in the blood and
approximately 20 mM in the skeletal muscle, is the most abundant
amino acid in the body [17,18]. However, the precise role
glutamine plays in regulating the skeletal muscle mass is not fully
understood. A recent review described the ability of glutamine to
regulate protein metabolism; however, the mechanism involved
was not addressed [19].
Glutamine is a readily tolerated, naturally occurring substance,
and the potential use of this amino acid for the treatment of
chronic diseases is under investigation. In this study, we evaluated
the possible beneficial effects of oral glutamine supplements on
skeletal muscle morphology, glutamine/glutamate content, protein
synthesis and degradation, determined by changes in the levels of
mRNA expression and the activation of signaling molecules
involved in protein synthesis (Akt, mTOR, GSK3 and 4E-BP1)
and degradation (MuRF-1 and MAFbx).
Materials and Methods
Animals
Male Wistar rats were obtained from and housed at the
Department of Physiology and Biophysics, Institute of Biomedical
Sciences, University of Sa˜o Paulo. The animals were maintained
at 2362uC under a cycle of 12-h light and 12-h darkness. The
animals had free access to food (Nuvilab CR1, Nuvital Nutrientes
Ltd., Curitiba, PR) and water. The animals were euthanized in a
fed state. The experimental procedures were performed in strict
accordance with the recommendations of the Guide for the Care
and Use of Laboratory Animals, and the Ethical Committee of the
Institute of Biomedical Sciences, University of Sa˜o Paulo (Permit
Number: 10/2008) approved this study. The animals were divided
into four groups; 1) control, non-supplemented with glutamine; 2)
control, supplemented with glutamine; 3) diabetic, non-supple-
mented with glutamine; and 4) diabetic, supplemented with
glutamine.
Induction of diabetes
The diabetic state was induced by a single intravenous injection
of 65 mg/kg bw streptozotocin (STZ) dissolved in citrate buffer
(pH 4.2). The control rats received an identical volume of buffer.
After 48 hours, a diabetic state was confirmed by blood glucose
levels above 200 mg/dL.
Oral L-glutamine supplementation
A solution of glutamine (Gln), freshly prepared and dissolved in
PBS, was administered by gavage once a day for 15 days
(supplemented and diabetic-supplemented animals). The daily
dose of glutamine (1 g/kg bw) was the same as previously
described [20]. The non-supplemented rats (control and diabetic)
received PBS alone. After 15 d of treatment, the plasma and
muscle glutamine contents were determined using the method
described by Windmueller and Spaeth [21].
Effect of glutamine supplementation on the expression
of signaling elements in protein synthetic and protein
degradation pathways in skeletal muscle
After 15 d of supplementation with glutamine, the soleus
muscles were removed and homogenized in extraction buffer
(100 mM Trizma, pH 7.5; 10 mM EDTA; 100 mM NaF; 10 mM
sodium pyrophosphate; 10 mM sodium orthovanadate; 2 mM
phenylmethanesulfonyl fluoride; and 0.01 mg/mL aprotinin) at
4uC for 30 sec. After homogenization, Triton X-100 was added to
a final concentration of 1%, the samples were incubated for
30 min at 4uC and were centrifuged at 13,0006 g for 20 min at
4uC. The total protein content was determined using bovine serum
albumin as the standard [22].
Equal amounts of protein from each sample (75 mg) were
diluted in Laemmli buffer containing dithiothreitol (DTT) (1 M)
and were submitted to electrophoresis on polyacrylamide gels. The
proteins were transblotted onto nitrocellulose membranes at
120 V for 1 h. The appearance of non-specific bands was blocked
by pre-incubation of the membranes in basal solution (10 mM
Trizma, pH 7.5; 150 mM NaCl; and 0.05% Tween 20) contain-
ing 5% skim milk at room temperature for 2 h. The membranes
were washed 3 times (10 min each) in basal solution and were
incubated with the following antibodies diluted in basal solution
containing 3% skim milk, at room temperature for 3 h: Akt
(1:1,000 dilution), phosphor Akt (pAkt) (1:1,000 dilution, Ser473),
mTOR (1:500 dilution), 4E-BP1 (1:1,000 dilution), MuRF-1
(1:500 dilution) and MAFbx (1:500 dilution). The membranes
were washed again (3610 min) and incubated with the corre-
sponding secondary antibody (1:5,000) conjugated to horseradish
peroxidase in basal solution, containing 1% skim milk, at room
temperature for 1 h. Following a final wash, the membranes were
incubated with the substrate for peroxidase and the chemilumi-
nescence enhancer solution (ECL Western Blotting System Kit,
GE Health Care, Little Chalfont, Buckinghamshire, England) for
1 min and were exposed immediately to X-ray film. The films
were processed, and the band intensities were quantified by optical
densitometry using the ImageJ 1.37 software (Wayne Rasband,
NIH, USA; http://rsb.info.nih.gov/ij/). The band densities were
normalized to an invariant band in membranes stained with
Ponceau S.
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Real-Time PCR
The mRNA expression of the selected genes was evaluated by
real-time PCR [23] using the ROTOR GENE 3000 apparatus
(Corbett Research, Mortlake, Australia). The total RNA was
obtained from 50 to 100 mg of the soleus muscle using Trizol
reagentTM (Invitrogen Life Technologies, Rockville, MD, USA).
Briefly, the soleus muscle was lysed using 1 mL Trizol reagent and
after 5 min incubation at room temperature, 200 mL chloroform
were added to the tubes, which were and centrifuged at 12,0006g.
The aqueous phase was transferred to a separate tube, and the
RNA was pelleted by centrifugation (12,0006 g) with isopropyl
alcohol. The RNA pellets were washed using 75% ethanol by
centrifugation at 7,5006g for 5 min and were air-dried. The RNA
pellets were eluted in RNase-free water and treated with DNAse I.
Subsequently, the RNA was stored at 270uC until the reverse
transcription procedure was performed. The RNA was quantified
by measuring the absorbance at 260 nm. The purity of the RNA
preparations was assessed by evaluating the 260/280 nm ratio and
on a 1% agarose gel stained with ethidium bromide at 5 mg/mL.
The cDNA probes were synthesized using 4 mg of the total
RNA and a mixture containing the following: 146 ng random
primers, 200 U reverse transcriptase (Invitrogen Life Technolo-
gies, Rockville, MD, USA), 56reaction buffer (50 mM Tris–HCl,
pH 8.0; 75 mM KCl; 3 mM MgCl2), 5 mM DTT, and 500 mM
dNTP in a final volume of 20 mL. The reaction was incubated for
2 min at 25uC, assembling the oligonucleotides and the RNA
hybridization, followed by heating at 42uC for 50 min. The cDNA
was stored at 220uC prior to the real-time PCR assay. For the
real-time PCR reaction, 1 mg of cDNA in a final volume of 25 mL
was used. The reaction mixture contained 100 mM dNTPs, 106
reaction buffer (10 mM Tris–HCl, 50 mM KCl, 2 mM MgCl2),
1 U Taq DNA polymerase (Invitrogen Life Technologies, Rock-
ville, MD, USA), 0.1 mM of each primer (sense and antisense), and
SYBR GREEN (diluted 1:1,000) (Invitrogen Life Technologies,
Rockville, MD, USA) was used as a fluorescent dye. The primer
sequences were designed using the information contained in the
Gene Bank of the National Center for Biotechnology Information
(NCBI). The sense and anti-sense sequences and the annealing
temperatures for Akt, 4E-BP1, GSK3, mTOR, MuRF-1, MAFbx,
YWHAZ and B2M are shown in Table 1.
The quantification of gene expression was performed using the
qBase software, as described previously [24]. B2M and YWHAZ
were used as the internal controls using the geNorm application
[25].
Histological analysis
A cryostat was used to cut the muscle sections (10-mm thick)
from the mid-belly region of the medial portion of the soleus
muscle. The sections were stained using hematoxylin and eosin
(HE) for the examination of the fiber cross-sectional area (CSA).
The sections were photographed using an upright microscope
equipped with a camera (Nikon DXM 1200, Japan). The digitized
images were analyzed using the Image Pro Plus Software (Media
Cybernetics, SilverSpring, MD) in a blinded manner. The mean
fiber CSA was determined by measuring the circumference of 100
adjacent fibers from the center of each cross-section, totaling 600
fibers per muscle tissue.
Statistical analysis
The data were analyzed using two-way analysis of variance
(ANOVA) and the Bonferroni post-hoc test. The results were
considered statistically significant at P,0.05. The GraphPad
Prism 5 software (Graph Pad Software, Inc., San Diego, CA, USA)
was used for the statistical analysis. For the histological analysis,
the muscle cross-sectional area data were analyzed using the
Anderson–Darling Normality Test. The muscle fiber CSA was not
normally distributed; therefore, differences were considered
significant when no overlap existed between the 95% confidence
interval of the mean (95% CI).
Results
The plasma glutamine levels exhibited a marked decrease
(,80%) in the diabetic animals compared to the controls
(Figure 1). In contrast, the plasma glutamate levels did not differ
significantly between the two groups (data not shown). Likewise,
the glutamine content of the soleus muscle was reduced to 30% of
the non-diabetic control value in the STZ-diabetic animals,
whereas the glutamate content was increased approximately 2-fold
in the diabetic samples (Figure 2). Consequently, the glutamine/
glutamate ratio of the muscle was decreased by 82% with the
induction of the diabetic state (Figure 2).
In both the plasma (Figure 1) and soleus muscle (Figure 2), the
glutamine supplementation of the diabetic animals (group DS)
resulted in a significantly higher glutamine content compared with
the non-supplemented diabetic controls (group D). The fold-
increase in plasma Gln was 3.2-fold in the Gln-supplemented
diabetic group (D vs. DS); however, exogenous Gln did not
significantly alter the plasma Gln concentration in the non-
diabetic animals (C vs. S). The glutamine/glutamate ratio in the
soleus muscle was also elevated in the Gln-supplemented diabetic
group compared with the non-supplemented diabetic group
(Figure 2C).
Figure 3 demonstrates the effect of exogenous glutamine on the
phosphorylation and gene expression of Akt. The diabetic animals
exhibited markedly reduced levels of phosphorylated Akt
(Figures 3A and B), with the ratio of pAkt to Akt decreasing
77% in these animals compared to the controls (Figure 3B). In
contrast, the induction of the diabetic state had no effect on the
mRNA levels of Akt (Figure 3C; C vs. D). The Gln supplemen-
tation did not change the Akt phosphorylation in the non-diabetic
animals (C vs. D) but increased the Akt phosphorylation
significantly (approximately 3-fold) in the diabetic animals (D vs.
DS) (Figure 3B). Moreover, the Akt mRNA transcript levels were
Table 1. Sequences of the primers, and annealing
temperatures for the Real Time PCR of the genes studied.
Gene Primer
Annealing
temperature (6C)
Akt Sense: GCCACAGGTCGCTACTATG 55.3
Anti-sense: GCAGGACACGGTTCTCAG
4E-BP1 Sense: CCTGATGGAGTGTCGGAAC 55.0
Anti-sense: GAGGCTCATCGCTGGTAG
GSK Sense: CCACTCAAGAACTGTCAAG 50.5
Anti-sense: CACGGTCTCCAGCATTAG
mTOR Sense: CAGGACGAGCGAGTGAT 55.4
Anti-sense: CGAGTTGGTGGACAGAGG
MuRF-1 Sense: CTATGGAGAACCTGGAGA 51.7
Anti-sense: CCTGGAAGATGTCGTTGG
MAF-bx Sense: TGCTTACAACTGAACATC 45.6
Anti-sense: TACATCTTCTTCCAATCC
doi:10.1371/journal.pone.0050390.t001
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increased approximately 2-fold by the Gln supplementation in
both the diabetic and non-diabetic animals (Figure 3C).
Unlike Akt, the diabetic state did not alter either the mTOR
protein content (Figure 4A) or the gene expression significantly
(Figure 4B). However, although the Gln supplementation failed to
alter the mTOR protein levels in the non-diabetic animals, an
almost 2-fold increase in the protein was observed in the diabetic
animals (Figure 4A). The Gln effect was not observed at the
mRNA level (Figure 4B). The induction of diabetes also failed to
alter either the activation protein or gene expression of GSK3
(data not shown).
Similar to Akt, the 4E-BP1 mRNA expression in the soleus
muscle was not altered significantly with the induction of diabetes
(Figure 5B; C vs. D). However, the 4E-BP1 protein content was
elevated significantly (48%) in the diabetic rats compared with the
non-diabetic animals (Figure 5A). This increase in the 4E-BP1
protein content and mRNA expression levels in the diabetic
animals was decreased significantly by the Gln supplementation
(Figure 5B).
Similar to mTOR and 4E-BP1, the protein degradation-
associated genes MuRF-1 and MAF-bx were altered by the
induction of diabetes, demonstrating significant increases at the
protein or mRNA levels, or both (Figures 6 and 7). Similarly to its
effect on 4E-BP1, Gln significantly reduced the mRNA levels of
both MuRF-1 and MAF-bx. However, Gln only affected MAF-bx
at the post-translational level, reducing the ubiquitin-related
protein by approximately 50% without affecting mRNA
(Figures 7A and 7B). The histological analysis of the soleus muscle
demonstrated a small but significant difference in the fiber-cross
sectional area between the control (1611612 mm2) and the
diabetic animals (1473613 mm2), reflecting the loss of the
myofibrils with the induction of diabetes (Figure 8). However,
the 15-day Gln-treatment did not affect fiber cross-sectional area
in either the non-diabetic (C vs. CS) or diabetic animals (D vs. DS)
(1611612 vs. 1643611 and 1473613 vs. 1466610, respectively).
Discussion
Our study demonstrates a number of significant differences in
glutamine regulation and in the protein-synthetic and protein-
degradative pathways in the skeletal muscle of the STZ-diabetic
rats compared with the non-diabetic rats. We also demonstrate
that the supplementation with exogenous glutamine reverses a
number of these changes, emphasizing the importance of this
amino acid in the etiology of diabetes and suggesting a potential
role for Gln supplementation in suppressing/reversing the muscle
loss associated with this disease.
A decrease in amino acid concentrations in the plasma has been
reported previously for a variety of catabolic diseases, including
diabetes [5,26,27] in which a reduction in the amino acid
glutamine was observed in the plasma and skeletal muscle [5]. The
underlying cause of the loss of skeletal-muscle Gln has been linked
to the metabolic sequelae of increased liver gluconeogenesis and
hyperglycemia [28].
In this study, we observed a significant reduction in plasma
glutamine concentrations in the diabetic model compared with the
non-diabetic animals, which is consistent with previous studies [5].
We also demonstrated that the glutamine supplementation
markedly increased the plasma concentration of this amino acid
in the diabetic rats but not in the non-diabetic rats. Although the
Gln content of the skeletal muscle is lowered in diabetes, the
glutamate content is increased, likely because of the increased
activity of phosphate-dependent glutaminase, resulting in de-
creased Gln but increased glutamate as a product of glutamine
deamination. The glutamine supplementation of the STZ-diabetic
rats partially compensated for the Gln loss in the plasma (Figure 1)
and restored the Gln content of the soleus to the non-diabetic
control levels (Figure 2). Therefore, it is reasonable to assume that
the oral administration of supplemental Gln resulted in sufficient
plasma and intramuscular concentrations of the amino acid to
alter the activity and/or expression of the signaling molecules in
the direction of increased protein synthesis and decreased
catabolism.
Akt is crucial to the potential role of Gln in attenuating diabetic
muscle wasting, and the post-translational activity (i.e., phosphor-
ylation) and in this study, the gene expression of Akt increased
significantly following Gln supplementation. Previous investiga-
tions have demonstrated atrophic changes in skeletal muscle
related to the reduced activity of Akt [1,29] under conditions of
mild insulinemia [3]. This study confirms the decreased activity of
Akt activation in the diabetic state and demonstrates that diabetes
affects neither the total protein content (data not shown) nor the
mRNA expression of Akt in skeletal muscles. Nonetheless, because
Gln supplementation increases Akt mRNA (Figure 3), Gln could
have a potentially beneficial effect on diabetic skeletal muscles by
increasing de novo Akt expression and synthesis.
Because Akt plays a key role in protein synthesis and protein
degradation pathways as an activator and inhibitor, respectively, it
is expected that following Gln supplementation, the restoration of
the Akt activity and expression levels found in the control will
prevent muscle wasting via the protective effects on both muscle
anabolism and catabolism. Supporting a role for Akt/Gln in
suppressing muscle breakdown, we demonstrate that both MuRF-
1 and MAF-bx protein levels were decreased significantly in the
diabetic rats receiving Gln (Figures 6 and 7).
In addition to insulin, several amino acids, leucine in particular,
regulate protein synthesis [30] through the activation of PI3K and
Akt. In one report, leucine supplementation in septic animals did
not modulate the expression of Akt [31]. However, another study
demonstrated that leucine treatment increased Akt phosphoryla-
tion in control mice treated with 1.5 mU/g of human insulin [32].
Leucine was also shown to ameliorate the increase in MAFbx and
MuRF-1 caused by muscle disuse [33]. We demonstrated that in a
diabetic rat model, treatment with glutamine (like leucine in earlier
reports) results in Akt activation in skeletal muscle and induces
increased Akt mRNA expression. These Gln-induced changes did
not require co-treatment with insulin. In addition, consistent with
the leucine effect on muscle disuse [33], the Gln supplementation
Figure 1. Plasma glutamine concentration (mM). The results are
expressed as the means6 SEM. The values represent 6 animals/group. *
p,0.05, as indicated by ANOVA and Bonferroni post-hoc test.
C = control rats; CS = control rats supplemented with glutamine;
D = diabetic rats; DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g001
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in the diabetic rats decreased the synthesis of the muscle-specific
ubiquitin ligases MAFbx and MuRF-1, likely downstream of the
phosphorylation of FOXO by Akt [12,34].
The similarities between the leucine- and glutamine-mediated
regulation of protein synthetic/degradative pathways may be in
part because both amino acids use the same heterodimeric
SLC7A5/SLC3A2 bidirectional transporter for influx (leucine) or
efflux (glutamine) from the cell [16,35]. This transporter uses
intracellular glutamine as an efflux substrate to take up extracel-
lular leucine and to activate mTORC1. Indeed, glutamine is an
Figure 2. Soleus muscle glutamine concentration (nmols/mg protein) (A); soleus muscle glutamate concentration (nmols/mg
protein) (B); glutamine/glutamate ratio (C). The results are expressed as the means 6 SEM. The values represent 6 animals/group. * p,0.05, as
indicated by ANOVA and the Bonferroni post-hoc test. C = control rats; CS = control rats supplemented with glutamine; D = diabetic rats; DS = diabetic
rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g002
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essential and rate-limiting factor for the activation of mTORC1 by
essential amino acids (such as leucine) and growth factors,
initiating the process of protein translation (described in the
Introduction). The intracellular glutamine required for the
activation of the bidirectional transporter enters the cell through
the high-affinity L-glutamine transporter SLC7A5 [16].
Of the signaling proteins examined in this study, the activity and
mRNA expression of only GSK3 was unchanged in the Gln-
supplemented rats compared with the control rats. GSK3 is
considered a key factor in the development of insulin resistance
and type II diabetes [36], and GSK3 inhibition improves skeletal
muscle insulin resistance in type II diabetic animals [37]. Our
demonstration of the effect of Gln is consistent with other reports
[38] showing that in the diabetic state, insulin and vanadium
treatments do not affect the GSK3 activity in the skeletal muscle.
The effects of insulin on muscle and other tissues may occur
directly through the activation of Akt and mTOR, or the effects
might be conveyed indirectly through changes in the intracellular
amino acid levels. Although not yet fully defined [39], evidence
suggests that the mechanism of insulin action may occur through
the activation of the class III PI3 kinase (hVps34) [40]. Therefore,
the low plasma insulin levels observed in the STZ-induced
Figure 3. Representative Western blots for phosphorylated and total Akt (A); pAkt/tAKT ratio (B); Akt mRNA expression (C). The
results are expressed as the means 6 SEM. The values represent 6 animals/group. * p,0.05, as indicated by ANOVA and the Bonferroni post-hoc test.
C = control rats; CS = control rats supplemented with glutamine; D = diabetic rats; DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g003
Figure 4. Representative Western blots for total mTOR protein content (A); mTOR mRNA expression (B). The results are expressed as
the means 6 SEM. The values represent 6 animals/group. * p,0.05, as indicated by ANOVA and the Bonferroni post-hoc test. C = control rats;
CS = control rats supplemented with glutamine; D = diabetic rats; DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g004
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diabetes is expected to lower the activation of Akt, as demonstrat-
ed in this study. However, our data also indicate that the diabetic
state did not influence the expression of the mTOR complex
(Figure 4). Remarkably, in the diabetic rats, Gln supplementation
increased the mTOR protein content to double that of the control
(Figure 4A). In contrast, the non-diabetic rats did not exhibit
increased levels of the mTOR protein following Gln supplemen-
tation. These results suggest that the diabetic state is required for
this particular Gln-mediated event in the protein synthetic
pathway to occur.
The diabetic state was also required for the effect of Gln
supplementation on the 4E-BP1, MuRF-1, and MAF-bx protein
content. It is plausible that the synthesis of these four proteins,
including mTOR (two of which are in the protein-synthetic
pathway and two are involved in protein degradation) is in some
way dependent on an insulin- or IGF-1-mediated alteration of a
common regulatory protein. However, the possible dependence of
these effects on insulin signal transduction is difficult to identify.
Knockout animals for the insulin receptor (MIRKO) that received
exogenous insulin exhibited decreased MAFbx (4-fold) and
MuRF-1 (2.3-fold) mRNA expression in the gastrocnemius
muscle, suggesting a signaling mechanism that largely bypasses
the insulin receptor. Regardless of the level that the glutamine
effect on the muscle is altered by diabetes, our results suggest that
at the clinical level, Gln supplementation is essentially ‘targeted’ to
diabetic individuals, producing little or no effect on muscle
function in normal individuals.
The histological analysis in this study clearly showed the
atrophic effect of STZ-diabetes in skeletal muscle; the cross-
sectional muscle fiber area was reduced by 9% (Figure 8).
However, in this study, Gln supplementation did not have a
significant effect on muscle atrophy, in either the diabetic or non-
diabetic animals. We speculate that the 15-day period of Gln
supplementation, although sufficient to detect molecular changes
in the muscle signaling pathways, was not sufficient to allow the
beneficial effects of Gln to be translated into an increase in the
muscle mass. In summary, this study identifies the specific
molecular changes in the skeletal muscle signaling pathways in
the STZ-diabetic rat, all of which are consistent with the eventual
loss of muscle mass characteristic of this disease. Our finding that
glutamine supplementation in the diabetic rats reversed most of
the deleterious changes in the signaling molecules suggests that
Figure 5. Representative Western blots for total 4E-BP1 protein content (A), 4E-BP1 mRNA expression (B). The results are expressed as
the means 6 SEM. The values represent 6 animals/group. * p,0.05, as indicated by ANOVA and the Bonferroni post-hoc test. C = control rats;
CS = control rats supplemented with glutamine; D = diabetic rats; DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g005
Figure 6. Representative Western blots for total MuRF-1 protein content (A); MuRF-1 mRNA expression (B). The results are expressed as
the means 6 SEM. The values represent 6 animals/group. * p,0.05, as indicated by ANOVA and the Bonferroni post-hoc test. C = control rats;
CS = control rats supplemented with glutamine; D = diabetic rats; DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g006
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Figure 7. Representative Western blots for total MAFbx protein content (A); MAFbx mRNA expression (B). The results are expressed as
the means 6 SEM. The values represent 6 animals/group. * p,0.05 as indicated by ANOVA and the Bonferroni post-hoc test. C = control rats;
CS = control rats supplemented with glutamine; D = diabetic rats; DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g007
Figure 8. Soleus cross-sectional area (mm2) analysis. The results are expressed as the means 6 SEM. The values represent 6 animals/group. *
p,0.05, as indicated by the Anderson–Darling Normality Test. C = control rats; CS = control rats supplemented with glutamine; D = diabetic rats;
DS = diabetic rats supplemented with glutamine.
doi:10.1371/journal.pone.0050390.g008
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oral supplementation with Gln could prove an inexpensive and
well-tolerated treatment for the progressive muscle wasting in
diabetes.
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